Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update

Background: Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached. Objective: Report 5-year OS and...

Full description

Saved in:
Bibliographic Details
Main Authors: Jessica S. W. Borgers, Theresa M. Medina, William A. Robinson, Kasey L. Couts, Elizabeth N. Katsnelson, Claire M. Muckle, Eduardo Davilla, Sapna P. Patel, Dexiang Gao, Richard P. Tobin, Martin D. McCarter
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251349321
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359251349321

Similar Items